FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Brigido Stephen 2. Issuer Name and Ticker or Trading Symbol GX Acquisition Corp. [ CELU ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Pres, Functional Regeneration
(Last)         (First)         (Middle)
C/O CELULARITY INC., 170 PARK AVENUE
3. Date of Earliest Transaction (MM/DD/YYYY)
7/16/2021
(Street)
FLORHAM PARK, NJ 07932
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)  $2.1829  7/16/2021    A     20379       (1) 7/16/2031  Class A Common Stock  20379  $0.00  20379  D   
Stock Option (Right to Buy)  $2.1829  7/16/2021    A     87872       (2) 7/16/2031  Class A Common Stock  87872  $0.00  87872  D   
Stock Option (Right to Buy)  $2.1829  7/16/2021    A     65846       (2) 7/16/2031  Class A Common Stock  65846  $0.00  65846  D   
Stock Option (Right to Buy)  $6.0258  7/16/2021    A     76859       (3) 7/16/2031  Class A Common Stock  76859  $0.00  76859  D   

Explanation of Responses:
(1)  This option shall vest and become exercisable over a period of four years from the Vesting Start Date, December 15, 2019, with 25% vesting on the one year anniversary of the Vesting Start Date, and the remainder vesting over a period of 36 months thereafter, subject to the Reporting Person's continuous service with the Issuer on each such date.
(2)  This option shall vest and become exercisable over a period of four years from the Vesting Start Date, August 30, 2019, with 25% vesting on the one year anniversary of the Vesting Start Date, and the remainder vesting over a period of 36 months thereafter, subject to the Reporting Person's continuous service with the Issuer on each such date.
(3)  This option is fully vested and exercisable.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Brigido Stephen
C/O CELULARITY INC.
170 PARK AVENUE
FLORHAM PARK, NJ 07932


Pres, Functional Regeneration

Signatures
/s/ Keary Dunn, Attorney-in-Fact 7/20/2021
**Signature of Reporting Person Date
GX Acquisition (NASDAQ:GXGX)
Historical Stock Chart
From Sep 2021 to Oct 2021 Click Here for more GX Acquisition Charts.
GX Acquisition (NASDAQ:GXGX)
Historical Stock Chart
From Oct 2020 to Oct 2021 Click Here for more GX Acquisition Charts.